The Interplay between Circulating Tumor Cells and the Immune System: From Immune Escape to Cancer Immunotherapy

Kevin Leone, Cristina Poggiana, Rita Zamarchi, Kevin Leone, Cristina Poggiana, Rita Zamarchi

Abstract

Circulating tumor cells (CTCs) have aroused increasing interest not only in mechanistic studies of metastasis, but also for translational applications, such as patient monitoring, treatment choice, and treatment change due to tumor resistance. In this review, we will assess the state of the art about the study of the interactions between CTCs and the immune system. We intend to analyze the impact that the cells of the immune system have in limiting or promoting the metastatic capability of CTCs. To this purpose, we will examine studies that correlate CTCs, immune cells, and patient prognosis, and we will also discuss relevant animal models that have contributed to the understanding of the mechanisms of immune-mediated metastasis. We will then consider some studies in which CTCs seem to play a promising role in monitoring cancer patients during immunotherapy regimens. We believe that, from an accurate and profound knowledge of the interactions between CTCs and the immune system, new immunotherapeutic strategies against cancer might emerge in the future.

Keywords: cancer biomarkers; circulating tumor cells; immune system; immunotherapy; liquid biopsy; metastasis.

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Representation of the main known mechanisms involving an interplay between CTCs and anti- or protumor cell populations of the immune system (+: induction).

References

    1. Lambert A.W., Pattabiraman D.R., Weinberg R.A. Emerging Biological Principles of Metastasis. Cell. 2017;168:670–691. doi: 10.1016/j.cell.2016.11.037.
    1. Braun S., Vogl F.D., Naume B., Janni W., Osborne M.P., Coombes R.C., Schlimok G., Diel I.J., Gerber B., Gebauer G., et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N. Engl. J. Med. 2005;353:793–802. doi: 10.1056/NEJMoa050434.
    1. Morgan T.M., Lange P.H., Porter M.P., Lin D.W., Ellis W.J., Gallaher I.S., Vessella R.L. Disseminated Tumor Cells in Prostate Cancer Patients after Radical Prostatectomy and without Evidence of Disease Predicts Biochemical Recurrence. Clin. Cancer Res. 2009;15:677–683. doi: 10.1158/1078-0432.CCR-08-1754.
    1. Hüsemann Y., Geigl J.B., Schubert F., Musiani P., Meyer M., Burghart E., Forni G., Eils R., Fehm T., Riethmüller G., et al. Systemic Spread Is an Early Step in Breast Cancer. Cancer Cell. 2008;13:58–68. doi: 10.1016/j.ccr.2007.12.003.
    1. Bidard F.C., Peeters D.J., Fehm T., Nolé F., Gisbert-Criado R., Mavroudis D., Grisanti S., Generali D., Garcia-Saenz J.A., Stebbing J., et al. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: A pooled analysis of individual patient data. Lancet Oncol. 2014;15:406–414. doi: 10.1016/S1470-2045(14)70069-5.
    1. Amadori A., Rossi E., Zamarchi R., Carli P., Pastorelli D., Jirillo A. Circulating and Disseminated Tumor Cells in the Clinical Management of Breast Cancer Patients: Unanswered Questions. Oncology. 2009;76:375–386. doi: 10.1159/000215581.
    1. Fidler I.J. Metastasis: Quantitative analysis of distribution and fate of tumor emboli labeled with 125 I-5-iodo-2′-deoxyuridine. J. Natl. Cancer Inst. 1970;45:773–782.
    1. Luzzi K.J., MacDonald I.C., Schmidt E.E., Kerkvliet N., Morris V.L., Chambers A.F., Groom A.C. Multistep nature of metastatic inefficiency: Dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am. J. Pathol. 1998;153:865–873. doi: 10.1016/S0002-9440(10)65628-3.
    1. Strilic B., Offermanns S. Intravascular Survival and Extravasation of Tumor Cells. Cancer Cell. 2017;32:282–293. doi: 10.1016/j.ccell.2017.07.001.
    1. Yu M., Bardia A., Wittner B.S., Stott S.L., Smas M.E., Ting D.T., Isakoff S.J., Ciciliano J.C., Wells M.N., Shah A.M., et al. Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition. Science. 2013;339:580–584. doi: 10.1126/science.1228522.
    1. Kitamura T., Qian B.-Z., Pollard J.W. Immune cell promotion of metastasis. Nat. Rev. Immunol. 2015;15:73–86. doi: 10.1038/nri3789.
    1. Mittal D., Gubin M.M., Schreiber R.D., Smyth M.J. New insights into cancer immunoediting and its three component phases—Elimination, equilibrium and escape. Curr. Opin. Immunol. 2014;27:16–25. doi: 10.1016/j.coi.2014.01.004.
    1. Kaplan R.N., Riba R.D., Zacharoulis S., Bramley A.H., Vincent L., Costa C., MacDonald D.D., Jin D.K., Shido K., Kerns S.A., et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature. 2005;438:820–827. doi: 10.1038/nature04186.
    1. Hiratsuka S., Watanabe A., Aburatani H., Maru Y. Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat. Cell Biol. 2006;8:1369–1375. doi: 10.1038/ncb1507.
    1. Luo J.-L., Maeda S., Hsu L.-C., Yagita H., Karin M. Inhibition of NF-κB in cancer cells converts inflammation-induced tumor growth mediated by TNFα to TRAIL-mediated tumor regression. Cancer Cell. 2004;6:297–305. doi: 10.1016/j.ccr.2004.08.012.
    1. Kim S., Takahashi H., Lin W.-W., Descargues P., Grivennikov S., Kim Y., Luo J.-L., Karin M. Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature. 2009;457:102–106. doi: 10.1038/nature07623.
    1. Cabioglu N., Sahin A.A., Morandi P., Meric-Bernstam F., Islam R., Lin H.Y., Bucana C.D., Gonzalez-Angulo A.M., Hortobagyi G.N., Cristofanilli M. Chemokine receptors in advanced breast cancer: Differential expression in metastatic disease sites with diagnostic and therapeutic implications. Ann. Oncol. 2009;20:1013–1019. doi: 10.1093/annonc/mdn740.
    1. Hensler M., Vančurová I., Becht E., Palata O., Strnad P., Tesařová P., Čabiňaková M., Švec D., Kubista M., Bartůňková J., et al. Gene expression profiling of circulating tumor cells and peripheral blood mononuclear cells from breast cancer patients. OncoImmunology. 2015;5:e1102827. doi: 10.1080/2162402X.2015.1102827.
    1. Santos M.F., Mannam V.K.R., Craft B.S., Puneky L.V., Sheehan N.T., Lewis R.E., Cruse J.M. Comparative analysis of innate immune system function in metastatic breast, colorectal, and prostate cancer patients with circulating tumor cells. Exp. Mol. Pathol. 2014;96:367–374. doi: 10.1016/j.yexmp.2014.04.001.
    1. Hanna N. Role of natural killer cells in control of cancer metastasis. Cancer Metastasis Rev. 1982;1:45–64. doi: 10.1007/BF00049480.
    1. Brodbeck T., Nehmann N., Bethge A., Wedemann G., Schumacher U. Perforin-dependent direct cytotoxicity in natural killer cells induces considerable knockdown of spontaneous lung metastases and computer modelling-proven tumor cell dormancy in a HT29 human colon cancer xenograft mouse model. Mol. Cancer. 2014;13:244. doi: 10.1186/1476-4598-13-244.
    1. López-Soto A., Gonzalez S., Smyth M.J., Galluzzi L. Control of Metastasis by NK Cells. Cancer Cell. 2017;32:135–154. doi: 10.1016/j.ccell.2017.06.009.
    1. Waldhauer I., Steinle A. NK cells and cancer immunosurveillance. Oncogene. 2008;27:5932–5943. doi: 10.1038/onc.2008.267.
    1. Green T.L., Cruse J.M., Lewis R.E. Circulating tumor cells (CTCs) from metastatic breast cancer patients linked to decreased immune function and response to treatment. Exp. Mol. Pathol. 2013;95:174–179. doi: 10.1016/j.yexmp.2013.06.013.
    1. Pagès F., Galon J., Dieu-Nosjean M.C., Tartour E., Sautès-Fridman C., Fridman W.H. Immune infiltration in human tumors: A prognostic factor that should not be ignored. Oncogene. 2009;29:1093–1102. doi: 10.1038/onc.2009.416.
    1. Gooden M.J.M., de Bock G.H., Leffers N., Daemen T., Nijman H.W. The prognostic influence of tumour-infiltrating lymphocytes in cancer: A systematic review with meta-analysis. Br. J. Cancer. 2011;105:93–103. doi: 10.1038/bjc.2011.189.
    1. De Giorgi U., Mego M., Scarpi E., Giuliano M., Giordano A., Reuben J.M., Valero V., Ueno N.T., Hortobagyi G.N., Cristofanilli M. Relationship Between Lymphocytopenia and Circulating Tumor Cells as Prognostic Factors for Overall Survival in Metastatic Breast Cancer. Clin. Breast Cancer. 2012;12:264–269. doi: 10.1016/j.clbc.2012.04.004.
    1. Mego M., Gao H., Cohen E.N., Anfossi S., Giordano A., Sanda T., Fouad T.M., De Giorgi U., Giuliano M., Woodward W.A., et al. Circulating Tumor Cells (CTC) Are Associated with Defects in Adaptive Immunity in Patients with Inflammatory Breast Cancer. J. Cancer. 2016;7:1095–1104. doi: 10.7150/jca.13098.
    1. Ye L., Zhang F., Li H., Yang L., Lv T., Gu W., Song Y. Circulating Tumor Cells Were Associated with the Number of T Lymphocyte Subsets and NK Cells in Peripheral Blood in Advanced Non-Small-Cell Lung Cancer. Dis. Mark. 2017;2017:5727815. doi: 10.1155/2017/5727815.
    1. Sun W.-W., Xu Z.-H., Lian P., Gao B.-L., Hu J.-A. Characteristics of circulating tumor cells in organ metastases, prognosis, and T lymphocyte mediated immune response. OncoTargets Ther. 2017;10:2413–2424. doi: 10.2147/OTT.S130087.
    1. Gruber I., Landenberger N., Staebler A., Hahn M., Wallwiener D., Fehm T. Relationship between circulating tumor cells and peripheral T-cells in patients with primary breast cancer. Anticancer Res. 2013;33:2233–2238.
    1. De Lafaille M.A.C., Lafaille J.J. Natural and Adaptive Foxp3+ Regulatory T Cells: More of the Same or a Division of Labor? Immunity. 2009;30:626–635. doi: 10.1016/j.immuni.2009.05.002.
    1. Dalotto-Moreno T., Croci D.O., Cerliani J.P., Martinez-Allo V.C., Dergan-Dylon S., Mendez-Huergo S.P., Stupirski J.C., Mazal D., Osinaga E., Toscano M.A., et al. Targeting Galectin-1 Overcomes Breast Cancer-Associated Immunosuppression and Prevents Metastatic Disease. Cancer Res. 2012;73:1107–1117. doi: 10.1158/0008-5472.CAN-12-2418.
    1. Jiang H., Gebhardt C., Umansky L., Beckhove P., Schulze T.J., Utikal J., Umansky V. Elevated chronic inflammatory factors and myeloid-derived suppressor cells indicate poor prognosis in advanced melanoma patients. Int. J. Cancer. 2015;136:2352–2360. doi: 10.1002/ijc.29297.
    1. Nakamura R., Sakakibara M., Nagashima T., Sangai T., Arai M., Fujimori T., Takano S., Shida T., Nakatani Y., Miyazaki M. Accumulation of regulatory T cells in sentinel lymph nodes is a prognostic predictor in patients with node-negative breast cancer. Eur. J. Cancer. 2009;45:2123–2131. doi: 10.1016/j.ejca.2009.03.024.
    1. Olkhanud P.B., Baatar D., Bodogai M., Hakim F., Gress R., Anderson R.L., Deng J., Xu M., Briest S., Biragyn A. Breast Cancer Lung Metastasis Requires Expression of Chemokine Receptor CCR4 and Regulatory T Cells. Cancer Res. 2009;69:5996–6004. doi: 10.1158/0008-5472.CAN-08-4619.
    1. Smyth M.J., Teng M.W.L., Swann J., Kyparissoudis K., Godfrey D.I., Hayakawa Y. CD4+CD25+ T Regulatory Cells Suppress NK Cell-Mediated Immunotherapy of Cancer. J. Immunol. 2006;176:1582–1587. doi: 10.4049/jimmunol.176.3.1582.
    1. Yang P., Li Q.-J., Feng Y., Zhang Y., Markowitz G.J., Ning S., Deng Y., Zhao J., Jiang S., Yuan Y., et al. TGF-β-miR-34a-CCL22 Signaling-Induced Treg Cell Recruitment Promotes Venous Metastases of HBV-Positive Hepatocellular Carcinoma. Cancer Cell. 2012;22:291–303. doi: 10.1016/j.ccr.2012.07.023.
    1. Chopra M., Riedel S.S., Biehl M., Krieger S., von Krosigk V., Bäuerlein C.A., Brede C., Jordan Garrote A.-L., Kraus S., Schäfer V., et al. Tumor necrosis factor receptor 2-dependent homeostasis of regulatory T cells as a player in TNF-induced experimental metastasis. Carcinogenesis. 2013;34:1296–1303. doi: 10.1093/carcin/bgt038.
    1. Stanzer S., Dandachi N., Balic M., Resel M., Samonigg H., Bauernhofer T. Resistance to Apoptosis and Expansion of Regulatory T Cells in Relation to the Detection of Circulating Tumor Cells in Patients with Metastatic Epithelial Cancer. J. Clin. Immunol. 2007;28:107–114. doi: 10.1007/s10875-007-9139-2.
    1. Zhou Y., Wang B., Wu J., Zhang C., Zhou Y., Yang X., Zhou J., Guo W., Fan J. Association of preoperative EpCAM Circulating Tumor Cells and peripheral Treg cell levels with early recurrence of hepatocellular carcinoma following radical hepatic resection. BMC Cancer. 2016;16:506. doi: 10.1186/s12885-016-2526-4.
    1. Tan W., Zhang W., Strasner A., Grivennikov S., Cheng J.Q., Hoffman R.M., Karin M. Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL–RANK signalling. Nature. 2011;470:548–553. doi: 10.1038/nature09707.
    1. Gray E.S., Reid A.L., Bowyer S., Calapre L., Siew K., Pearce R., Cowell L., Frank M.H., Millward M., Ziman M. Circulating Melanoma Cell Subpopulations: Their Heterogeneity and Differential Responses to Treatment. J. Investig. Dermatol. 2015;135:2040–2048. doi: 10.1038/jid.2015.127.
    1. Coffelt S.B., Kersten K., Doornebal C.W., Weiden J., Vrijland K., Hau C.-S., Verstegen N.J.M., Ciampricotti M., Hawinkels L.J.A.C., Jonkers J., et al. IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis. Nature. 2015;522:345–348. doi: 10.1038/nature14282.
    1. Kersten K., Coffelt S.B., Hoogstraat M., Verstegen N.J.M., Vrijland K., Ciampricotti M., Doornebal C.W., Hau C.-S., Wellenstein M.D., Salvagno C., et al. Mammary tumor-derived CCL2 enhances pro-metastatic systemic inflammation through upregulation of IL1β in tumor-associated macrophages. OncoImmunology. 2017;6:e1334744. doi: 10.1080/2162402X.2017.1334744.
    1. Novitskiy S.V., Pickup M.W., Gorska A.E., Owens P., Chytil A., Aakre M., Wu H., Shyr Y., Moses H.L. TGF-Receptor II Loss Promotes Mammary Carcinoma Progression by Th17-Dependent Mechanisms. Cancer Discov. 2011;1:430–441. doi: 10.1158/-11-0100.
    1. Tseng J.Y., Yang C.Y., Liang S.C., Liu R.S., Yang S.H., Lin J.K., Chen Y.M., Wu Y.C., Jiang J.K., Lin C.H. Interleukin-17A Modulates Circulating Tumor Cells in Tumor Draining Vein of Colorectal Cancers and Affects Metastases. Clin. Cancer Res. 2014;20:2885–2897. doi: 10.1158/1078-0432.CCR-13-2162.
    1. Wei L.E.I., Wang H.U.I., Yang F.E.N., Ding Q.I., Zhao J. Interleukin-17 potently increases non-small cell lung cancer growth. Mol. Med. Rep. 2016;13:1673–1680. doi: 10.3892/mmr.2015.4694.
    1. Li Q., Han Y., Fei G., Guo Z., Ren T., Liu Z. IL-17 promoted metastasis of non-small-cell lung cancer cells. Immunol. Lett. 2012;148:144–150. doi: 10.1016/j.imlet.2012.10.011.
    1. Pan B., Shen J., Cao J., Zhou Y., Shang L., Jin S., Cao S., Che D., Liu F., Yu Y. Interleukin-17 promotes angiogenesis by stimulating VEGF production of cancer cells via the STAT3/GIV signaling pathway in non-small-cell lung cancer. Sci. Rep. 2015;5:16053. doi: 10.1038/srep16053.
    1. Wen Z., Liao Q., Zhao J., Hu Y., You L., Lu Z., Jia C., Wei Y., Zhao Y. High Expression of Interleukin-22 and Its Receptor Predicts Poor Prognosis in Pancreatic Ductal Adenocarcinoma. Ann. Surg. Oncol. 2013;21:125–132. doi: 10.1245/s10434-013-3322-x.
    1. Monteiro A.C., Leal A.C., Goncalves-Silva T., Mercadante A.C., Kestelman F., Chaves S.B., Azevedo R.B., Monteiro J.P., Bonomo A. T cells induce pre-metastatic osteolytic disease and help bone metastases establishment in a mouse model of metastatic breast cancer. PLoS ONE. 2013;8:e68171. doi: 10.1371/journal.pone.0068171.
    1. Taranova A.G., Maldonado D., Vachon C.M., Jacobsen E.A., Abdala-Valencia H., McGarry M.P., Ochkur S.I., Protheroe C.A., Doyle A., Grant C.S., et al. Allergic Pulmonary Inflammation Promotes the Recruitment of Circulating Tumor Cells to the Lung. Cancer Res. 2008;68:8582–8589. doi: 10.1158/0008-5472.CAN-08-1673.
    1. Bodogai M., Moritoh K., Lee-Chang C., Hollander C.M., Sherman-Baust C.A., Wersto R.P., Araki Y., Miyoshi I., Yang L., Trinchieri G., et al. Immunosuppressive and Prometastatic Functions of Myeloid-Derived Suppressive Cells Rely upon Education from Tumor-Associated B Cells. Cancer Res. 2015;75:3456–3465. doi: 10.1158/0008-5472.CAN-14-3077.
    1. Gasteiger G., Fan X., Dikiy S., Lee S.Y., Rudensky A.Y. Tissue residency of innate lymphoid cells in lymphoid and nonlymphoid organs. Science. 2015;350:981–985. doi: 10.1126/science.aac9593.
    1. Saranchova I., Han J., Zaman R., Arora H., Huang H., Fenninger F., Choi K.B., Munro L., Pfeifer C.G., Welch I., et al. Type 2 Innate Lymphocytes Actuate Immunity Against Tumours and Limit Cancer Metastasis. Sci. Rep. 2018;8:2924. doi: 10.1038/s41598-018-20608-6.
    1. Shojaei F., Wu X., Qu X., Kowanetz M., Yu L., Tan M., Meng Y.G., Ferrara N. G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc. Natl. Acad. Sci. USA. 2009;106:6742–6747. doi: 10.1073/pnas.0902280106.
    1. Kowanetz M., Wu X., Lee J., Tan M., Hagenbeek T., Qu X., Yu L., Ross J., Korsisaari N., Cao T., et al. Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes. Proc. Natl. Acad. Sci. USA. 2010;107:21248–21255. doi: 10.1073/pnas.1015855107.
    1. Granot Z., Henke E., Comen E.A., King T.A., Norton L., Benezra R. Tumor Entrained Neutrophils Inhibit Seeding in the Premetastatic Lung. Cancer Cell. 2011;20:300–314. doi: 10.1016/j.ccr.2011.08.012.
    1. Coffelt S.B., Wellenstein M.D., de Visser K.E. Neutrophils in cancer: Neutral no more. Nat. Rev. Cancer. 2016;16:431–446. doi: 10.1038/nrc.2016.52.
    1. Bald T., Quast T., Landsberg J., Rogava M., Glodde N., Lopez-Ramos D., Kohlmeyer J., Riesenberg S., van den Boorn-Konijnenberg D., Hömig-Hölzel C., et al. Ultraviolet-radiation-induced inflammation promotes angiotropism and metastasis in melanoma. Nature. 2014;507:109–113. doi: 10.1038/nature13111.
    1. McDonald B., Spicer J., Giannais B., Fallavollita L., Brodt P., Ferri L.E. Systemic inflammation increases cancer cell adhesion to hepatic sinusoids by neutrophil mediated mechanisms. Int. J. Cancer. 2009;125:1298–1305. doi: 10.1002/ijc.24409.
    1. Spicer J.D., McDonald B., Cools-Lartigue J.J., Chow S.C., Giannias B., Kubes P., Ferri L.E. Neutrophils Promote Liver Metastasis via Mac-1-Mediated Interactions with Circulating Tumor Cells. Cancer Res. 2012;72:3919–3927. doi: 10.1158/0008-5472.CAN-11-2393.
    1. Huh S.J., Liang S., Sharma A., Dong C., Robertson G.P. Transiently Entrapped Circulating Tumor Cells Interact with Neutrophils to Facilitate Lung Metastasis Development. Cancer Res. 2010;70:6071–6082. doi: 10.1158/0008-5472.CAN-09-4442.
    1. Strell C., Lang K., Niggemann B., Zaenker K.S., Entschladen F. Neutrophil granulocytes promote the migratory activity of MDA-MB-468 human breast carcinoma cells via ICAM-1. Exp. Cell Res. 2010;316:138–148. doi: 10.1016/j.yexcr.2009.09.003.
    1. Cools-Lartigue J., Spicer J., McDonald B., Gowing S., Chow S., Giannias B., Bourdeau F., Kubes P., Ferri L. Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis. J. Clin. Investig. 2013;123:3446–3458. doi: 10.1172/JCI67484.
    1. Tohme S., Yazdani H.O., Al-Khafaji A.B., Chidi A.P., Loughran P., Mowen K., Wang Y., Simmons R.L., Huang H., Tsung A. Neutrophil Extracellular Traps Promote the Development and Progression of Liver Metastases after Surgical Stress. Cancer Res. 2016;76:1367–1380. doi: 10.1158/0008-5472.CAN-15-1591.
    1. Park J., Wysocki R.W., Amoozgar Z., Maiorino L., Fein M.R., Jorns J., Schott A.F., Kinugasa-Katayama Y., Lee Y., Won N.H., et al. Cancer cells induce metastasis-supporting neutrophil extracellular DNA traps. Sci. Transl. Med. 2016;8:361ra138. doi: 10.1126/scitranslmed.aag1711.
    1. Demers M., Krause D.S., Schatzberg D., Martinod K., Voorhees J.R., Fuchs T.A., Scadden D.T., Wagner D.D. Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancer-associated thrombosis. Proc. Natl. Acad. Sci. USA. 2012;109:13076–13081. doi: 10.1073/pnas.1200419109.
    1. Najmeh S., Cools-Lartigue J., Rayes R.F., Gowing S., Vourtzoumis P., Bourdeau F., Giannias B., Berube J., Rousseau S., Ferri L.E., et al. Neutrophil extracellular traps sequester circulating tumor cells via β1-integrin mediated interactions. Int. J. Cancer. 2017;140:2321–2330. doi: 10.1002/ijc.30635.
    1. Boone B.A., Orlichenko L., Schapiro N.E., Loughran P., Gianfrate G.C., Ellis J.T., Singhi A.D., Kang R., Tang D., Lotze M.T., et al. The receptor for advanced glycation end products (RAGE) enhances autophagy and neutrophil extracellular traps in pancreatic cancer. Cancer Gene Ther. 2015;22:326–334. doi: 10.1038/cgt.2015.21.
    1. Yang C., Sun W., Cui W., Li X., Yao J., Jia X., Li C., Wu H., Hu Z., Zou X. Procoagulant role of neutrophil extracellular traps in patients with gastric cancer. Int. J. Clin. Exp. Pathol. 2015;8:14075–14086.
    1. Auffray C., Fogg D., Garfa M., Elain G., Join-Lambert O., Kayal S., Sarnacki S., Cumano A., Lauvau G., Geissmann F. Monitoring of Blood Vessels and Tissues by a Population of Monocytes with Patrolling Behavior. Science. 2007;317:666–670. doi: 10.1126/science.1142883.
    1. Hanna R.N., Cekic C., Sag D., Tacke R., Thomas G.D., Nowyhed H., Herrley E., Rasquinha N., McArdle S., Wu R., et al. Patrolling monocytes control tumor metastasis to the lung. Science. 2015;350:985–990. doi: 10.1126/science.aac9407.
    1. Ostrand-Rosenberg S., Fenselau C. Myeloid-Derived Suppressor Cells: Immune-Suppressive Cells That Impair Antitumor Immunity and Are Sculpted by Their Environment. J. Immunol. 2018;200:422–431. doi: 10.4049/jimmunol.1701019.
    1. Huang A., Zhang B., Wang B., Zhang F., Fan K.-X., Guo Y.-J. Increased CD14+HLA-DR-/low myeloid-derived suppressor cells correlate with extrathoracic metastasis and poor response to chemotherapy in non-small cell lung cancer patients. Cancer Immunology, Immunotherapy. 2013;62:1439–1451. doi: 10.1007/s00262-013-1450-6.
    1. Diaz-Montero C.M., Salem M.L., Nishimura M.I., Garrett-Mayer E., Cole D.J., Montero A.J. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapy. Cancer Immunology, Immunotherapy. 2008;58:49–59. doi: 10.1007/s00262-008-0523-4.
    1. Yu J., Du W., Yan F., Wang Y., Li H., Cao S., Yu W., Shen C., Liu J., Ren X. Myeloid-Derived Suppressor Cells Suppress Antitumor Immune Responses through IDO Expression and Correlate with Lymph Node Metastasis in Patients with Breast Cancer. J. Immunol. 2013;190:3783–3797. doi: 10.4049/jimmunol.1201449.
    1. Arnoletti J.P., Zhu X., Almodovar A.J.O., Veldhuis P.P., Sause R., Griffith E., Corpus G., Chang J.C.C., Fanaian N., Litherland S.A. Portal Venous Blood Circulation Supports Immunosuppressive Environment and Pancreatic Cancer Circulating Tumor Cell Activation. Pancreas. 2017;46:116–123. doi: 10.1097/MPA.0000000000000667.
    1. Oh K., Lee O.Y., Shon S.Y., Nam O., Ryu P.M., Seo M.W., Lee D.S. A mutual activation loop between breast cancer cells and myeloid-derived suppressor cells facilitates spontaneous metastasis through IL-6 trans-signaling in a murine model. Breast Cancer Res. 2013;15:R79. doi: 10.1186/bcr3473.
    1. Yang L., DeBusk L.M., Fukuda K., Fingleton B., Green-Jarvis B., Shyr Y., Matrisian L.M., Carbone D.P., Lin P.C. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell. 2004;6:409–421. doi: 10.1016/j.ccr.2004.08.031.
    1. Yang L., Huang J., Ren X., Gorska A.E., Chytil A., Aakre M., Carbone D.P., Matrisian L.M., Richmond A., Lin P.C., et al. Abrogation of TGFβ Signaling in Mammary Carcinomas Recruits Gr-1+CD11b+ Myeloid Cells that Promote Metastasis. Cancer Cell. 2008;13:23–35. doi: 10.1016/j.ccr.2007.12.004.
    1. Yan H.H., Pickup M., Pang Y., Gorska A.E., Li Z., Chytil A., Geng Y., Gray J.W., Moses H.L., Yang L. Gr-1+CD11b+ Myeloid Cells Tip the Balance of Immune Protection to Tumor Promotion in the Premetastatic Lung. Cancer Res. 2010;70:6139–6149. doi: 10.1158/0008-5472.CAN-10-0706.
    1. Toh B., Wang X., Keeble J., Sim W.J., Khoo K., Wong W.C., Kato M., Prevost-Blondel A., Thiery J.P., Abastado J.P. Mesenchymal transition and dissemination of cancer cells is driven by myeloid-derived suppressor cells infiltrating the primary tumor. PLoS Biol. 2011;9:e1001162. doi: 10.1371/journal.pbio.1001162.
    1. Ouzounova M., Lee E., Piranlioglu R., El Andaloussi A., Kolhe R., Demirci M.F., Marasco D., Asm I., Chadli A., Hassan K.A., et al. Monocytic and granulocytic myeloid derived suppressor cells differentially regulate spatiotemporal tumour plasticity during metastatic cascade. Nat. Commun. 2017;8:14979. doi: 10.1038/ncomms14979.
    1. Bayon L.G., Izquierdo M.A., Sirovich I., van Rooijen N., Beelen R.H., Meijer S. Role of Kupffer cells in arresting circulating tumor cells and controlling metastatic growth in the liver. Hepatology. 1996;23:1224–1231. doi: 10.1002/hep.510230542.
    1. Deneve E., Riethdorf S., Ramos J., Nocca D., Coffy A., Daures J.P., Maudelonde T., Fabre J.M., Pantel K., Alix-Panabieres C. Capture of Viable Circulating Tumor Cells in the Liver of Colorectal Cancer Patients. Clin. Chem. 2013;59:1384–1392. doi: 10.1373/clinchem.2013.202846.
    1. Gül N., Babes L., Siegmund K., Korthouwer R., Bögels M., Braster R., Vidarsson G., ten Hagen T.L.M., Kubes P., van Egmond M. Macrophages eliminate circulating tumor cells after monoclonal antibody therapy. J. Clin. Investig. 2014;124:812–823. doi: 10.1172/JCI66776.
    1. Franklin R.A., Liao W., Sarkar A., Kim M.V., Bivona M.R., Liu K., Pamer E.G., Li M.O. The cellular and molecular origin of tumor-associated macrophages. Science. 2014;344:921–925. doi: 10.1126/science.1252510.
    1. Sica A., Mantovani A. Macrophage plasticity and polarization: In vivo veritas. J. Clin. Investig. 2012;122:787–795. doi: 10.1172/JCI59643.
    1. Qian B.-Z., Pollard J.W. Macrophage Diversity Enhances Tumor Progression and Metastasis. Cell. 2010;141:39–51. doi: 10.1016/j.cell.2010.03.014.
    1. Song L., Asgharzadeh S., Salo J., Engell K., Wu H.-w., Sposto R., Ara T., Silverman A.M., DeClerck Y.A., Seeger R.C., et al. Vα24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages. J. Clin. Investig. 2009;119:1524–1536. doi: 10.1172/JCI37869.
    1. Steidl C., Lee T., Shah S.P., Farinha P., Han G., Nayar T., Delaney A., Jones S.J., Iqbal J., Weisenburger D.D., et al. Tumor-associated macrophages and survival in classic Hodgkin’s lymphoma. N. Engl. J. Med. 2010;362:875–885. doi: 10.1056/NEJMoa0905680.
    1. Wyckoff J., Wang W., Lin E.Y., Wang Y., Pixley F., Stanley E.R., Graf T., Pollard J.W., Segall J., Condeelis J. A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors. Cancer Res. 2004;64:7022–7029. doi: 10.1158/0008-5472.CAN-04-1449.
    1. Wyckoff J.B., Wang Y., Lin E.Y., Li J.F., Goswami S., Stanley E.R., Segall J.E., Pollard J.W., Condeelis J. Direct Visualization of Macrophage-Assisted Tumor Cell Intravasation in Mammary Tumors. Cancer Res. 2007;67:2649–2656. doi: 10.1158/0008-5472.CAN-06-1823.
    1. Sangaletti S., Di Carlo E., Gariboldi S., Miotti S., Cappetti B., Parenza M., Rumio C., Brekken R.A., Chiodoni C., Colombo M.P. Macrophage-Derived SPARC Bridges Tumor Cell-Extracellular Matrix Interactions toward Metastasis. Cancer Res. 2008;68:9050–9059. doi: 10.1158/0008-5472.CAN-08-1327.
    1. Yang M., Chen J., Su F., Yu B., Lin L., Liu Y., Huang J.D., Song E. Microvesicles secreted by macrophages shuttle invasion-potentiating microRNAs into breast cancer cells. Mol. Cancer. 2011;10:117. doi: 10.1186/1476-4598-10-117.
    1. Chen J., Yao Y., Gong C., Yu F., Su S., Chen J., Liu B., Deng H., Wang F., Lin L., et al. CCL18 from Tumor-Associated Macrophages Promotes Breast Cancer Metastasis via PITPNM3. Cancer Cell. 2011;19:541–555. doi: 10.1016/j.ccr.2011.02.006.
    1. Liu B., Jia Y., Ma J., Wu S., Jiang H., Cao Y., Sun X., Yin X., Yan S., Shang M., et al. Tumor-associated macrophage-derived CCL20 enhances the growth and metastasis of pancreatic cancer. Acta Biochim. Biophys. Sin. 2016;48:1067–1074. doi: 10.1093/abbs/gmw101.
    1. Ören B., Urosevic J., Mertens C., Mora J., Guiu M., Gomis R.R., Weigert A., Schmid T., Grein S., Brüne B., et al. Tumour stroma-derived lipocalin-2 promotes breast cancer metastasis. J. Pathol. 2016;239:274–285. doi: 10.1002/path.4724.
    1. Ho M.Y., Tang S.J., Chuang M.J., Cha T.L., Li J.Y., Sun G.H., Sun K.H. TNF-Induces Epithelial-Mesenchymal Transition of Renal Cell Carcinoma Cells via a GSK3-Dependent Mechanism. Mol. Cancer Res. 2012;10:1109–1119. doi: 10.1158/1541-7786.MCR-12-0160.
    1. Fu X.T., Dai Z., Song K., Zhang Z.J., Zhou Z.J., Zhou S.L., Zhao Y.M., Xiao Y.S., Sun Q.M., Ding Z.B., et al. Macrophage-secreted IL-8 induces epithelial-mesenchymal transition in hepatocellular carcinoma cells by activating the JAK2/STAT3/Snail pathway. Int. J. Oncol. 2015;46:587–596. doi: 10.3892/ijo.2014.2761.
    1. Lee C.-H., Liu S.-Y., Chou K.-C., Yeh C.-T., Shiah S.-G., Huang R.-Y., Cheng J.-C., Yen C.-Y., Shieh Y.-S. Tumor-Associated Macrophages Promote Oral Cancer Progression Through Activation of the Axl Signaling Pathway. Ann. Surg. Oncol. 2013;21:1031–1037. doi: 10.1245/s10434-013-3400-0.
    1. Sullivan N.J., Sasser A.K., Axel A.E., Vesuna F., Raman V., Ramirez N., Oberyszyn T.M., Hall B.M. Interleukin-6 induces an epithelial–mesenchymal transition phenotype in human breast cancer cells. Oncogene. 2009;28:2940–2947. doi: 10.1038/onc.2009.180.
    1. Kawata M., Koinuma D., Ogami T., Umezawa K., Iwata C., Watabe T., Miyazono K. TGF-β-induced epithelial-mesenchymal transition of A549 lung adenocarcinoma cells is enhanced by pro-inflammatory cytokines derived from RAW 264.7 macrophage cells. J. Biochem. 2012;151:205–216. doi: 10.1093/jb/mvr136.
    1. Fan Q.-M., Jing Y.-Y., Yu G.-F., Kou X.-R., Ye F., Gao L., Li R., Zhao Q.-D., Yang Y., Lu Z.-H., et al. Tumor-associated macrophages promote cancer stem cell-like properties via transforming growth factor-beta1-induced epithelial–mesenchymal transition in hepatocellular carcinoma. Cancer Lett. 2014;352:160–168. doi: 10.1016/j.canlet.2014.05.008.
    1. Roh-Johnson M., Bravo-Cordero J.J., Patsialou A., Sharma V.P., Guo P., Liu H., Hodgson L., Condeelis J. Macrophage contact induces RhoA GTPase signaling to trigger tumor cell intravasation. Oncogene. 2013;33:4203–4212. doi: 10.1038/onc.2013.377.
    1. Pignatelli J., Bravo-Cordero J.J., Roh-Johnson M., Gandhi S.J., Wang Y., Chen X., Eddy R.J., Xue A., Singer R.H., Hodgson L., et al. Macrophage-dependent tumor cell transendothelial migration is mediated by Notch1/MenaINV-initiated invadopodium formation. Sci. Rep. 2016;6:37874. doi: 10.1038/srep37874.
    1. Hamilton G., Rath B., Klameth L., Hochmair M.J. Small cell lung cancer: Recruitment of macrophages by circulating tumor cells. OncoImmunology. 2015;5:e1093277. doi: 10.1080/2162402X.2015.1093277.
    1. Qian B.-Z., Li J., Zhang H., Kitamura T., Zhang J., Campion L.R., Kaiser E.A., Snyder L.A., Pollard J.W. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature. 2011;475:222–225. doi: 10.1038/nature10138.
    1. Zhao L., Lim S.Y., Gordon-Weeks A.N., Tapmeier T.T., Im J.H., Cao Y., Beech J., Allen D., Smart S., Muschel R.J. Recruitment of a myeloid cell subset (CD11b/Gr1mid) via CCL2/CCR2 promotes the development of colorectal cancer liver metastasis. Hepatology. 2013;57:829–839. doi: 10.1002/hep.26094.
    1. Qian B., Deng Y., Im J.H., Muschel R.J., Zou Y., Li J., Lang R.A., Pollard J.W. A distinct macrophage population mediates metastatic breast cancer cell extravasation, establishment and growth. PLoS ONE. 2009;4:e6562. doi: 10.1371/journal.pone.0006562.
    1. Hiratsuka S., Nakamura K., Iwai S., Murakami M., Itoh T., Kijima H., Shipley J.M., Senior R.M., Shibuya M. MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell. 2002;2:289–300. doi: 10.1016/S1535-6108(02)00153-8.
    1. Gil-Bernabe A.M., Ferjancic S., Tlalka M., Zhao L., Allen P.D., Im J.H., Watson K., Hill S.A., Amirkhosravi A., Francis J.L., et al. Recruitment of monocytes/macrophages by tissue factor-mediated coagulation is essential for metastatic cell survival and premetastatic niche establishment in mice. Blood. 2012;119:3164–3175. doi: 10.1182/blood-2011-08-376426.
    1. Headley M.B., Bins A., Nip A., Roberts E.W., Looney M.R., Gerard A., Krummel M.F. Visualization of immediate immune responses to pioneer metastatic cells in the lung. Nature. 2016;531:513–517. doi: 10.1038/nature16985.
    1. Kitamura T., Qian B.-Z., Soong D., Cassetta L., Noy R., Sugano G., Kato Y., Li J., Pollard J.W. CCL2-induced chemokine cascade promotes breast cancer metastasis by enhancing retention of metastasis-associated macrophages. J. Exp. Med. 2015;212:1043–1059. doi: 10.1084/jem.20141836.
    1. Chen Q., Zhang X.H.F., Massagué J. Macrophage Binding to Receptor VCAM-1 Transmits Survival Signals in Breast Cancer Cells that Invade the Lungs. Cancer Cell. 2011;20:538–549. doi: 10.1016/j.ccr.2011.08.025.
    1. Sevenich L., Bowman R.L., Mason S.D., Quail D.F., Rapaport F., Elie B.T., Brogi E., Brastianos P.K., Hahn W.C., Holsinger L.J., et al. Analysis of tumour- and stroma-supplied proteolytic networks reveals a brain-metastasis-promoting role for cathepsin S. Nat. Cell Biol. 2014;16:876–888. doi: 10.1038/ncb3011.
    1. Ma Y., Shurin G.V., Peiyuan Z., Shurin M.R. Dendritic Cells in the Cancer Microenvironment. J. Cancer. 2013;4:36–44. doi: 10.7150/jca.5046.
    1. Tran Janco J.M., Lamichhane P., Karyampudi L., Knutson K.L. Tumor-Infiltrating Dendritic Cells in Cancer Pathogenesis. J. Immunol. 2015;194:2985–2991. doi: 10.4049/jimmunol.1403134.
    1. Miyagawa S., Soeda J., Takagi S., Miwa S., Ichikawa E., Noike T. Prognostic significance of mature dendritic cells and factors associated with their accumulation in metastatic liver tumors from colorectal cancer. Hum. Pathol. 2004;35:1392–1396. doi: 10.1016/j.humpath.2004.07.018.
    1. Lijun Z., Xin Z., Danhua S., Xiaoping L., Jianliu W., Huilan W., Lihui W. Tumor-Infiltrating Dendritic Cells May Be Used as Clinicopathologic Prognostic Factors in Endometrial Carcinoma. Int. J. Gynecol. Cancer. 2012;22:836–841. doi: 10.1097/IGC.0b013e31825401c6.
    1. Green T.L., Santos M.F., Ejaeidi A.A., Craft B.S., Lewis R.E., Cruse J.M. Toll-like receptor (TLR) expression of immune system cells from metastatic breast cancer patients with circulating tumor cells. Exp. Mol. Pathol. 2014;97:44–48. doi: 10.1016/j.yexmp.2014.05.003.
    1. Herber D.L., Cao W., Nefedova Y., Novitskiy S.V., Nagaraj S., Tyurin V.A., Corzo A., Cho H.-I., Celis E., Lennox B., et al. Lipid accumulation and dendritic cell dysfunction in cancer. Nat. Med. 2010;16:880–886. doi: 10.1038/nm.2172.
    1. Mego M., Gao H., Cohen E.N., Anfossi S., Giordano A., Tin S., Fouad T.M., De Giorgi U., Giuliano M., Woodward W.A., et al. Circulating tumor cells (CTCs) are associated with abnormalities in peripheral blood dendritic cells in patients with inflammatory breast cancer. Oncotarget. 2017;8:35656–35668. doi: 10.18632/oncotarget.10290.
    1. Kudo-Saito C., Shirako H., Ohike M., Tsukamoto N., Kawakami Y. CCL2 is critical for immunosuppression to promote cancer metastasis. Clin. Exp. Metastasis. 2012;30:393–405. doi: 10.1007/s10585-012-9545-6.
    1. Kenkel J.A., Tseng W.W., Davidson M.G., Tolentino L.L., Choi O., Bhattacharya N., Seeley E.S., Winer D.A., Reticker-Flynn N.E., Engleman E.G. An Immunosuppressive Dendritic Cell Subset Accumulates at Secondary Sites and Promotes Metastasis in Pancreatic Cancer. Cancer Res. 2017;77:4158–4170. doi: 10.1158/0008-5472.CAN-16-2212.
    1. Shen Y., Guo D., Weng L., Wang S., Ma Z., Yang Y., Wang P., Wang J., Cai Z. Tumor-derived exosomes educate dendritic cells to promote tumor metastasis via HSP72/HSP105-TLR2/TLR4 pathway. OncoImmunology. 2017;6:e1362527. doi: 10.1080/2162402X.2017.1362527.
    1. Pryczynicz A., Cepowicz D., Zaręba K., Gryko M., Hołody-Zaręba J., Kędra B., Kemona A., Guzińska-Ustymowicz K. Dysfunctions in the Mature Dendritic Cells Are Associated with the Presence of Metastases of Colorectal Cancer in the Surrounding Lymph Nodes. Gastroenterol. Res. Pract. 2016;2016:2405437. doi: 10.1155/2016/2405437.
    1. Sawant A., Hensel J.A., Chanda D., Harris B.A., Siegal G.P., Maheshwari A., Ponnazhagan S. Depletion of Plasmacytoid Dendritic Cells Inhibits Tumor Growth and Prevents Bone Metastasis of Breast Cancer Cells. J. Immunol. 2012;189:4258–4265. doi: 10.4049/jimmunol.1101855.
    1. Conrad C., Gregorio J., Wang Y.H., Ito T., Meller S., Hanabuchi S., Anderson S., Atkinson N., Ramirez P.T., Liu Y.J., et al. Plasmacytoid Dendritic Cells Promote Immunosuppression in Ovarian Cancer via ICOS Costimulation of Foxp3+ T-Regulatory Cells. Cancer Res. 2012;72:5240–5249. doi: 10.1158/0008-5472.CAN-12-2271.
    1. Gerlini G., Urso C., Mariotti G., Di Gennaro P., Palli D., Brandani P., Salvadori A., Pimpinelli N., Reali U.M., Borgognoni L. Plasmacytoid dendritic cells represent a major dendritic cell subset in sentinel lymph nodes of melanoma patients and accumulate in metastatic nodes. Clin. Immunol. 2007;125:184–193. doi: 10.1016/j.clim.2007.07.018.
    1. Liu W., Zhao J., Li Q., Wang Q., Zhou Y., Tong Z. Gastric cancer patients have elevated plasmacytoid and CD1c+ dendritic cells in the peripheral blood. Oncol. Lett. 2018;15:5087–5092. doi: 10.3892/ol.2018.7990.
    1. Küsters B., Kats G., Roodink I., Verrijp K., Wesseling P., Ruiter D.J., de Waal R.M.W., Leenders W.P.J. Micronodular transformation as a novel mechanism of VEGF-A-induced metastasis. Oncogene. 2007;26:5808–5815. doi: 10.1038/sj.onc.1210360.
    1. Borsig L., Wong R., Hynes R.O., Varki N.M., Varki A. Synergistic effects of L- and P-selectin in facilitating tumor metastasis can involve non-mucin ligands and implicate leukocytes as enhancers of metastasis. Proc. Natl. Acad. Sci. USA. 2002;99:2193–2198. doi: 10.1073/pnas.261704098.
    1. Duda D.G., Duyverman A.M., Kohno M., Snuderl M., Steller E.J., Fukumura D., Jain R.K. Malignant cells facilitate lung metastasis by bringing their own soil. Proc. Natl. Acad. Sci. USA. 2010;107:21677–21682. doi: 10.1073/pnas.1016234107.
    1. Jiang X., Wong K.H.K., Khankhel A.H., Zeinali M., Reategui E., Phillips M.J., Luo X., Aceto N., Fachin F., Hoang A.N., et al. Microfluidic isolation of platelet-covered circulating tumor cells. Lab Chip. 2017;17:3498–3503. doi: 10.1039/C7LC00654C.
    1. Adams D.L., Martin S.S., Alpaugh R.K., Charpentier M., Tsai S., Bergan R.C., Ogden I.M., Catalona W., Chumsri S., Tang C.M., et al. Circulating giant macrophages as a potential biomarker of solid tumors. Proc. Natl. Acad. Sci. USA. 2014;111:3514–3519. doi: 10.1073/pnas.1320198111.
    1. Adams D.L., Adams D.K., Alpaugh R.K., Cristofanilli M., Martin S.S., Chumsri S., Tang C.M., Marks J.R. Circulating Cancer-Associated Macrophage-Like Cells Differentiate Malignant Breast Cancer and Benign Breast Conditions. Cancer Epidemiol. Biomark. Prev. 2016;25:1037–1042. doi: 10.1158/1055-9965.EPI-15-1221.
    1. Clawson G.A., Matters G.L., Xin P., Imamura-Kawasawa Y., Du Z., Thiboutot D.M., Helm K.F., Neves R.I., Abraham T. Macrophage-tumor cell fusions from peripheral blood of melanoma patients. PLoS ONE. 2015;10:e0134320. doi: 10.1371/journal.pone.0134320.
    1. Adams D.L., Adams D.K., He J., Kalhor N., Zhang M., Xu T., Gao H., Reuben J.M., Qiao Y., Komaki R., et al. Sequential Tracking of PD-L1 Expression and RAD50 Induction in Circulating Tumor and Stromal Cells of Lung Cancer Patients Undergoing Radiotherapy. Clin. Cancer Res. 2017;23:5948–5958. doi: 10.1158/1078-0432.CCR-17-0802.
    1. Mu Z., Wang C., Ye Z., Rossi G., Sun C., Li L., Zhu Z., Yang H., Cristofanilli M. Prognostic values of cancer associated macrophage-like cells (CAML) enumeration in metastatic breast cancer. Breast Cancer Res. Treat. 2017;165:733–741. doi: 10.1007/s10549-017-4372-8.
    1. Mohme M., Riethdorf S., Pantel K. Circulating and disseminated tumour cells—Mechanisms of immune surveillance and escape. Nat. Rev. Clin. Oncol. 2016;14:155–167. doi: 10.1038/nrclinonc.2016.144.
    1. Watson N.F.S., Ramage J.M., Madjd Z., Spendlove I., Ellis I.O., Scholefield J.H., Durrant L.G. Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis. Int. J. Cancer. 2006;118:6–10. doi: 10.1002/ijc.21303.
    1. Placke T., Orgel M., Schaller M., Jung G., Rammensee H.G., Kopp H.G., Salih H.R. Platelet-Derived MHC Class I Confers a Pseudonormal Phenotype to Cancer Cells That Subverts the Antitumor Reactivity of Natural Killer Immune Cells. Cancer Res. 2011;72:440–448. doi: 10.1158/0008-5472.CAN-11-1872.
    1. Wu M.S., Li C.H., Ruppert J.G., Chang C.C. Cytokeratin 8-MHC class I interactions: A potential novel immune escape phenotype by a lymph node metastatic carcinoma cell line. Biochem. Biophys. Res. Commun. 2013;441:618–623. doi: 10.1016/j.bbrc.2013.10.105.
    1. Mazel M., Jacot W., Pantel K., Bartkowiak K., Topart D., Cayrefourcq L., Rossille D., Maudelonde T., Fest T., Alix-Panabières C. Frequent expression of PD-L1 on circulating breast cancer cells. Mol. Oncol. 2015;9:1773–1782. doi: 10.1016/j.molonc.2015.05.009.
    1. Nicolazzo C., Raimondi C., Mancini M., Caponnetto S., Gradilone A., Gandini O., Mastromartino M., del Bene G., Prete A., Longo F., et al. Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab. Sci. Rep. 2016;6:31726. doi: 10.1038/srep31726.
    1. Yue C., Jiang Y., Li P., Wang Y., Xue J., Li N., Li D., Wang R., Dang Y., Hu Z., et al. Dynamic change of PD-L1 expression on circulating tumor cells in advanced solid tumor patients undergoing PD-1 blockade therapy. OncoImmunology. 2018;7:e1438111. doi: 10.1080/2162402X.2018.1438111.
    1. Kallergi G., Vetsika E.-K., Aggouraki D., Lagoudaki E., Koutsopoulos A., Koinis F., Katsarlinos P., Trypaki M., Messaritakis I., Stournaras C., et al. Evaluation of PD-L1/PD-1 on circulating tumor cells in patients with advanced non-small cell lung cancer. Ther. Adv. Med. Oncol. 2018;10 doi: 10.1177/1758834017750121.
    1. Chao M.P., Tang C., Pachynski R.K., Chin R., Majeti R., Weissman I.L. Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy. Blood. 2011;118:4890–4901. doi: 10.1182/blood-2011-02-338020.
    1. Baccelli I., Schneeweiss A., Riethdorf S., Stenzinger A., Schillert A., Vogel V., Klein C., Saini M., Bäuerle T., Wallwiener M., et al. Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat. Biotechnol. 2013;31:539–544. doi: 10.1038/nbt.2576.
    1. Steinert G., Schölch S., Niemietz T., Iwata N., García S.A., Behrens B., Voigt A., Kloor M., Benner A., Bork U., et al. Immune Escape and Survival Mechanisms in Circulating Tumor Cells of Colorectal Cancer. Cancer Res. 2014;74:1694–1704. doi: 10.1158/0008-5472.CAN-13-1885.
    1. Hallermalm K., De Geer A., Kiessling R., Levitsky V., Levitskaya J. Autocrine secretion of Fas ligand shields tumor cells from Fas-mediated killing by cytotoxic lymphocytes. Cancer Res. 2004;64:6775–6782. doi: 10.1158/0008-5472.CAN-04-0508.
    1. Hong Y., Fang F., Zhang Q. Circulating tumor cell clusters: What we know and what we expect. Int. J. Oncol. 2016;49:2206–2216. doi: 10.3892/ijo.2016.3747.
    1. Labelle M., Begum S., Hynes R.O. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell. 2011;20:576–590. doi: 10.1016/j.ccr.2011.09.009.
    1. Weber M.R., Zuka M., Lorger M., Tschan M., Torbett B.E., Zijlstra A., Quigley J.P., Staflin K., Eliceiri B.P., Krueger J.S., et al. Activated tumor cell integrin αvβ3 cooperates with platelets to promote extravasation and metastasis from the blood stream. Thromb. Res. 2016;140:S27–S36. doi: 10.1016/S0049-3848(16)30095-0.
    1. Nieswandt B., Hafner M., Echtenacher B., Mannel D.N. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res. 1999;59:1295–1300.
    1. Sneath R.J., Mangham D.C. The normal structure and function of CD44 and its role in neoplasia. Mol. Pathol. 1998;51:191–200. doi: 10.1136/mp.51.4.191.
    1. Borsig L., Wong R., Feramisco J., Nadeau D.R., Varki N.M., Varki A. Heparin and cancer revisited: Mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc. Natl. Acad. Sci. USA. 2001;98:3352–3357. doi: 10.1073/pnas.061615598.
    1. Gunthert U., Hofmann M., Rudy W., Reber S., Zoller M., Haussmann I., Matzku S., Wenzel A., Ponta H., Herrlich P. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell. 1991;65:13–24. doi: 10.1016/0092-8674(91)90403-L.
    1. Katoh S., Goi T., Naruse T., Ueda Y., Kurebayashi H., Nakazawa T., Kimura Y., Hirono Y., Yamaguchi A. Cancer stem cell marker in circulating tumor cells: Expression of CD44 variant exon 9 is strongly correlated to treatment refractoriness, recurrence and prognosis of human colorectal cancer. Anticancer Res. 2015;35:239–244.
    1. Oldenborg P.A., Zheleznyak A., Fang Y.F., Lagenaur C.F., Gresham H.D., Lindberg F.P. Role of CD47 as a marker of self on red blood cells. Science. 2000;288:2051–2054. doi: 10.1126/science.288.5473.2051.
    1. Gardai S.J., McPhillips K.A., Frasch S.C., Janssen W.J., Starefeldt A., Murphy-Ullrich J.E., Bratton D.L., Oldenborg P.A., Michalak M., Henson P.M. Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell. 2005;123:321–334. doi: 10.1016/j.cell.2005.08.032.
    1. Keir M.E., Butte M.J., Freeman G.J., Sharpe A.H. PD-1 and Its Ligands in Tolerance and Immunity. Ann. Rev. Immunol. 2008;26:677–704. doi: 10.1146/annurev.immunol.26.021607.090331.
    1. Wang X., Teng F., Kong L., Yu J. PD-L1 expression in human cancers and its association with clinical outcomes. OncoTargets Ther. 2016;9:5023–5039.
    1. Anantharaman A., Friedlander T., Lu D., Krupa R., Premasekharan G., Hough J., Edwards M., Paz R., Lindquist K., Graf R., et al. Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients. BMC Cancer. 2016;16:744. doi: 10.1186/s12885-016-2758-3.
    1. Guibert N., Delaunay M., Lusque A., Boubekeur N., Rouquette I., Clermont E., Mourlanette J., Gouin S., Dormoy I., Favre G., et al. PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab. Lung Cancer. 2018;120:108–112. doi: 10.1016/j.lungcan.2018.04.001.
    1. Dhar M., Wong J., Che J., Matsumoto M., Grogan T., Elashoff D., Garon E.B., Goldman J.W., Sollier Christen E., Di Carlo D., et al. Evaluation of PD-L1 expression on vortex-isolated circulating tumor cells in metastatic lung cancer. Sci. Rep. 2018;8:2592. doi: 10.1038/s41598-018-19245-w.
    1. Strati A., Koutsodontis G., Papaxoinis G., Angelidis I., Zavridou M., Economopoulou P., Kotsantis I., Avgeris M., Mazel M., Perisanidis C., et al. Prognostic significance of PD-L1 expression on circulating tumor cells in patients with head and neck squamous cell carcinoma. Ann. Oncol. 2017;28:1923–1933. doi: 10.1093/annonc/mdx206.
    1. Teo J., Mirenska A., Tan M., Lee Y., Oh J., Hong L.Z., Wnek R., Yap Y.S., Shih S.J., AA S.B., et al. A preliminary study for the assessment of PD-L1 and PD-L2 on circulating tumor cells by microfluidic-based chipcytometry. Future Sci. OA. 2017;3:FSO244. doi: 10.4155/fsoa-2017-0079.
    1. Ilié M., Szafer-Glusman E., Hofman V., Chamorey E., Lalvée S., Selva E., Leroy S., Marquette C.H., Kowanetz M., Hedge P., et al. Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer. Ann. Oncol. 2018;29:193–199. doi: 10.1093/annonc/mdx636.
    1. Schnell U., Cirulli V., Giepmans B.N.G. EpCAM: Structure and function in health and disease. Biochim. Biophys. Acta (BBA) Biomembr. 2013;1828:1989–2001. doi: 10.1016/j.bbamem.2013.04.018.
    1. Manicone M., Poggiana C., Facchinetti A., Zamarchi R. Critical issues in the clinical application of liquid biopsy in non-small cell lung cancer. J. Thorac. Dis. 2017;9:S1346–S1358. doi: 10.21037/jtd.2017.07.28.
    1. Parkinson D.R., Dracopoli N., Petty B.G., Compton C., Cristofanilli M., Deisseroth A., Hayes D.F., Kapke G., Kumar P., Lee J.S.H., et al. Considerations in the development of circulating tumor cell technology for clinical use. J. Transl. Med. 2012;10:138. doi: 10.1186/1479-5876-10-138.
    1. van der Gun B.T.F., Melchers L.J., Ruiters M.H.J., de Leij L.F.M.H., McLaughlin P.M.J., Rots M.G. EpCAM in carcinogenesis: The good, the bad or the ugly. Carcinogenesis. 2010;31:1913–1921. doi: 10.1093/carcin/bgq187.
    1. Gorges T.M., Tinhofer I., Drosch M., Rose L., Zollner T.M., Krahn T., von Ahsen O. Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition. BMC Cancer. 2012;12:178. doi: 10.1186/1471-2407-12-178.
    1. Terry S., Savagner P., Ortiz-Cuaran S., Mahjoubi L., Saintigny P., Thiery J.-P., Chouaib S. New insights into the role of EMT in tumor immune escape. Mol. Oncol. 2017;11:824–846. doi: 10.1002/1878-0261.12093.
    1. Akalay I., Janji B., Hasmim M., Noman M.Z., Andre F., De Cremoux P., Bertheau P., Badoual C., Vielh P., Larsen A.K., et al. Epithelial-to-Mesenchymal Transition and Autophagy Induction in Breast Carcinoma Promote Escape from T-cell-Mediated Lysis. Cancer Res. 2013;73:2418–2427. doi: 10.1158/0008-5472.CAN-12-2432.
    1. Satelli A., Mitra A., Brownlee Z., Xia X., Bellister S., Overman M.J., Kopetz S., Ellis L.M., Meng Q.H., Li S. Epithelial-mesenchymal transitioned circulating tumor cells capture for detecting tumor progression. Clin. Cancer Res. 2015;21:899–906. doi: 10.1158/1078-0432.CCR-14-0894.
    1. Lampignano R., Schneck H., Neumann M., Fehm T., Neubauer H. Enrichment, Isolation and Molecular Characterization of EpCAM-Negative Circulating Tumor Cells. Adv. Exp. Med. Biol. 2017;994:181–203.
    1. Papaioannou N.E., Beniata O.V., Vitsos P., Tsitsilonis O., Samara P. Harnessing the immune system to improve cancer therapy. Ann. Transl. Med. 2016;4:261. doi: 10.21037/atm.2016.04.01.
    1. Madic J., Kiialainen A., Bidard F.C., Birzele F., Ramey G., Leroy Q., Rio Frio T., Vaucher I., Raynal V., Bernard V., et al. Circulating tumor DNA and circulating tumor cells in metastatic triple negative breast cancer patients. Int. J. Cancer. 2015;136:2158–2165. doi: 10.1002/ijc.29265.
    1. Chiavenna S.M., Jaworski J.P., Vendrell A. State of the art in anti-cancer mAbs. J. Biomed. Sci. 2017;24:15. doi: 10.1186/s12929-016-0311-y.
    1. Vallera D.A., Zhang B., Gleason M.K., Oh S., Weiner L.M., Kaufman D.S., McCullar V., Miller J.S., Verneris M.R. Heterodimeric bispecific single-chain variable-fragment antibodies against EpCAM and CD16 induce effective antibody-dependent cellular cytotoxicity against human carcinoma cells. Cancer Biother. Radiopharm. 2013;28:274–282. doi: 10.1089/cbr.2012.1329.
    1. Prang N., Preithner S., Brischwein K., Goster P., Woppel A., Muller J., Steiger C., Peters M., Baeuerle P.A., da Silva A.J. Cellular and complement-dependent cytotoxicity of Ep-CAM-specific monoclonal antibody MT201 against breast cancer cell lines. Br. J. Cancer. 2005;92:342–349. doi: 10.1038/sj.bjc.6602310.
    1. Scaltriti M., Baselga J. The epidermal growth factor receptor pathway: A model for targeted therapy. Clin. Cancer Res. 2006;12:5268–5272. doi: 10.1158/1078-0432.CCR-05-1554.
    1. Salomon D.S., Brandt R., Ciardiello F., Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol. 1995;19:183–232. doi: 10.1016/1040-8428(94)00144-I.
    1. Payne R.E., Yague E., Slade M.J., Apostolopoulos C., Jiao L.R., Ward B., Coombes R.C., Stebbing J. Measurements of EGFR expression on circulating tumor cells are reproducible over time in metastatic breast cancer patients. Pharmacogenomics. 2009;10:51–57. doi: 10.2217/14622416.10.1.51.
    1. Punnoose E.A., Atwal S.K., Spoerke J.M., Savage H., Pandita A., Yeh R.F., Pirzkall A., Fine B.M., Amler L.C., Chen D.S., et al. Molecular biomarker analyses using circulating tumor cells. PLoS ONE. 2010;5:e12517. doi: 10.1371/journal.pone.0012517.
    1. Shaffer D.R., Leversha M.A., Danila D.C., Lin O., Gonzalez-Espinoza R., Gu B., Anand A., Smith K., Maslak P., Doyle G.V., et al. Circulating Tumor Cell Analysis in Patients with Progressive Castration-Resistant Prostate Cancer. Clin. Cancer Res. 2007;13:2023–2029. doi: 10.1158/1078-0432.CCR-06-2701.
    1. Gorges T.M., Stein A., Quidde J., Hauch S., Rock K., Riethdorf S., Joosse S.A., Pantel K. Improved Detection of Circulating Tumor Cells in Metastatic Colorectal Cancer by the Combination of the CellSearch(R) System and the AdnaTest(R) PLoS ONE. 2016;11:e0155126. doi: 10.1371/journal.pone.0155126.
    1. Gasch C., Bauernhofer T., Pichler M., Langer-Freitag S., Reeh M., Seifert A.M., Mauermann O., Izbicki J.R., Pantel K., Riethdorf S. Heterogeneity of Epidermal Growth Factor Receptor Status and Mutations of KRAS/PIK3CA in Circulating Tumor Cells of Patients with Colorectal Cancer. Clin. Chem. 2012;59:252–260. doi: 10.1373/clinchem.2012.188557.
    1. Musella V., Pietrantonio F., Di Buduo E., Iacovelli R., Martinetti A., Sottotetti E., Bossi I., Maggi C., Di Bartolomeo M., de Braud F., et al. Circulating tumor cells as a longitudinal biomarker in patients with advanced chemorefractory, RAS-BRAFwild-type colorectal cancer receiving cetuximab or panitumumab. Int. J. Cancer. 2015;137:1467–1474. doi: 10.1002/ijc.29493.
    1. Kuboki Y., Matsusaka S., Minowa S., Shibata H., Suenaga M., Shinozaki E., Mizunuma N., Ueno M., Yamaguchi T., Hatake K. Circulating tumor cell (CTC) count and epithelial growth factor receptor expression on CTCs as biomarkers for cetuximab efficacy in advanced colorectal cancer. Anticancer Res. 2013;33:3905–3910.
    1. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177–182. doi: 10.1126/science.3798106.
    1. Meng S., Tripathy D., Shete S., Ashfaq R., Haley B., Perkins S., Beitsch P., Khan A., Euhus D., Osborne C., et al. HER-2 gene amplification can be acquired as breast cancer progresses. Proc. Natl. Acad. Sci. USA. 2004;101:9393–9398. doi: 10.1073/pnas.0402993101.
    1. Fehm T., Muller V., Aktas B., Janni W., Schneeweiss A., Stickeler E., Lattrich C., Lohberg C.R., Solomayer E., Rack B., et al. HER2 status of circulating tumor cells in patients with metastatic breast cancer: A prospective, multicenter trial. Breast Cancer Res. Treat. 2010;124:403–412. doi: 10.1007/s10549-010-1163-x.
    1. Pestrin M., Bessi S., Galardi F., Truglia M., Biggeri A., Biagioni C., Cappadona S., Biganzoli L., Giannini A., Di Leo A. Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients. Breast Cancer Res. Treat. 2009;118:523–530. doi: 10.1007/s10549-009-0461-7.
    1. Munzone E., Nolé F., Goldhirsch A., Botteri E., Esposito A., Zorzino L., Curigliano G., Minchella I., Adamoli L., Cassatella M.C., et al. Changes of HER2 Status in Circulating Tumor Cells Compared With the Primary Tumor During Treatment for Advanced Breast Cancer. Clin. Breast Cancer. 2010;10:392–397. doi: 10.3816/CBC.2010.n.052.
    1. Ignatiadis M., Rothe F., Chaboteaux C., Durbecq V., Rouas G., Criscitiello C., Metallo J., Kheddoumi N., Singhal S.K., Michiels S., et al. HER2-positive circulating tumor cells in breast cancer. PLoS ONE. 2011;6:e15624. doi: 10.1371/journal.pone.0015624.
    1. Zhang S., Li L., Wang T., Bian L., Hu H., Xu C., Liu B., Liu Y., Cristofanilli M., Jiang Z. Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patients. BMC Cancer. 2016;16:526. doi: 10.1186/s12885-016-2578-5.
    1. D’Oronzo S., Brown J., Coleman R. The role of biomarkers in the management of bone-homing malignancies. J. Bone Oncol. 2017;9:1–9. doi: 10.1016/j.jbo.2017.09.001.
    1. Jones D.H., Nakashima T., Sanchez O.H., Kozieradzki I., Komarova S.V., Sarosi I., Morony S., Rubin E., Sarao R., Hojilla C.V., et al. Regulation of cancer cell migration and bone metastasis by RANKL. Nature. 2006;440:692–696. doi: 10.1038/nature04524.
    1. Santini D., Schiavon G., Vincenzi B., Gaeta L., Pantano F., Russo A., Ortega C., Porta C., Galluzzo S., Armento G., et al. Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients. PLoS ONE. 2011;6:e19234. doi: 10.1371/journal.pone.0019234.
    1. Schieferdecker A., Voigt M., Riecken K., Braig F., Schinke T., Loges S., Bokemeyer C., Fehse B., Binder M. Denosumab mimics the natural decoy receptor osteoprotegerin by interacting with its major binding site on RANKL. Oncotarget. 2014;5:6647–6653. doi: 10.18632/oncotarget.2160.
    1. Buchbinder E.I., Desai A. CTLA-4 and PD-1 Pathways. Am. J. Clin. Oncol. 2016;39:98–106. doi: 10.1097/COC.0000000000000239.
    1. Linsley P.S., Bradshaw J., Greene J., Peach R., Bennett K.L., Mittler R.S. Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement. Immunity. 1996;4:535–543. doi: 10.1016/S1074-7613(00)80480-X.
    1. Krummel M.F., Allison J.P. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J. Exp. Med. 1995;182:459–465. doi: 10.1084/jem.182.2.459.
    1. Guinan E.C., Gribben J.G., Boussiotis V.A., Freeman G.J., Nadler L.M. Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity. Blood. 1994;84:3261–3282.
    1. Tarhini A., Lo E., Minor D.R. Releasing the brake on the immune system: Ipilimumab in melanoma and other tumors. Cancer Biother. Radiopharm. 2010;25:601–613. doi: 10.1089/cbr.2010.0865.
    1. Martens A., Wistuba-Hamprecht K., Yuan J., Postow M.A., Wong P., Capone M., Madonna G., Khammari A., Schilling B., Sucker A., et al. Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab. Clin. Cancer Res. 2016;22:4848–4858. doi: 10.1158/1078-0432.CCR-16-0249.
    1. Damuzzo V., Solito S., Pinton L., Carrozzo E., Valpione S., Pigozzo J., Arboretti Giancristofaro R., Chiarion-Sileni V., Mandruzzato S. Clinical implication of tumor-associated and immunological parameters in melanoma patients treated with ipilimumab. OncoImmunology. 2016;5:e1249559. doi: 10.1080/2162402X.2016.1249559.
    1. Jamal R., Lapointe R., Cocolakis E., Thébault P., Kazemi S., Friedmann J.E., Dionne J., Cailhier J.-F., Bélanger K., Ayoub J.-P., et al. Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma. J. ImmunoTher. Cancer. 2017;5:83. doi: 10.1186/s40425-017-0290-x.
    1. Chatenoud L., Tarhini A.A., Edington H., Butterfield L.H., Lin Y., Shuai Y., Tawbi H., Sander C., Yin Y., Holtzman M., et al. Immune Monitoring of the Circulation and the Tumor Microenvironment in Patients with Regionally Advanced Melanoma Receiving Neoadjuvant Ipilimumab. PLoS ONE. 2014;9:e87705.
    1. Khoja L., Lorigan P., Zhou C., Lancashire M., Booth J., Cummings J., Califano R., Clack G., Hughes A., Dive C. Biomarker Utility of Circulating Tumor Cells in Metastatic Cutaneous Melanoma. J. Investig. Dermatol. 2013;133:1582–1590. doi: 10.1038/jid.2012.468.
    1. Klinac D., Gray E.S., Freeman J.B., Reid A., Bowyer S., Millward M., Ziman M. Monitoring changes in circulating tumour cells as a prognostic indicator of overall survival and treatment response in patients with metastatic melanoma. BMC Cancer. 2014;14:423. doi: 10.1186/1471-2407-14-423.
    1. Hong X., Sullivan R.J., Kalinich M., Kwan T.T., Giobbie-Hurder A., Pan S., LiCausi J.A., Milner J.D., Nieman L.T., Wittner B.S., et al. Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy. Proc. Natl. Acad. Sci. USA. 2018;115:2467–2472. doi: 10.1073/pnas.1719264115.
    1. Alsaab H.O., Sau S., Alzhrani R., Tatiparti K., Bhise K., Kashaw S.K., Iyer A.K. PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome. Front. Pharmacol. 2017;8:561. doi: 10.3389/fphar.2017.00561.
    1. Patel S.P., Kurzrock R. PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. Mol. Cancer Ther. 2015;14:847–856. doi: 10.1158/1535-7163.MCT-14-0983.
    1. Meng X., Huang Z., Teng F., Xing L., Yu J. Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy. Cancer Treat. Rev. 2015;41:868–876. doi: 10.1016/j.ctrv.2015.11.001.
    1. Callea M., Albiges L., Gupta M., Cheng S.C., Genega E.M., Fay A.P., Song J., Carvo I., Bhatt R.S., Atkins M.B., et al. Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma. Cancer Immunol. Res. 2015;3:1158–1164. doi: 10.1158/2326-6066.CIR-15-0043.
    1. Rosenberg S.A., Restifo N.P., Yang J.C., Morgan R.A., Dudley M.E. Adoptive cell transfer: A clinical path to effective cancer immunotherapy. Nat. Rev. Cancer. 2008;8:299–308. doi: 10.1038/nrc2355.
    1. Rosenberg S.A., Packard B.S., Aebersold P.M., Solomon D., Topalian S.L., Toy S.T., Simon P., Lotze M.T., Yang J.C., Seipp C.A., et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N. Engl. J. Med. 1988;319:1676–1680. doi: 10.1056/NEJM198812223192527.
    1. Rosenberg S.A., Yang J.C., Sherry R.M., Kammula U.S., Hughes M.S., Phan G.Q., Citrin D.E., Restifo N.P., Robbins P.F., Wunderlich J.R., et al. Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy. Clin. Cancer Res. 2011;17:4550–4557. doi: 10.1158/1078-0432.CCR-11-0116.
    1. Fousek K., Ahmed N. The Evolution of T-cell Therapies for Solid Malignancies. Clin. Cancer Res. 2015;21:3384–3392. doi: 10.1158/1078-0432.CCR-14-2675.
    1. Liang S., Xu K., Niu L., Wang X., Liang Y., Zhang M., Chen J., Lin M. Comparison of autogeneic and allogeneic natural killer cells immunotherapy on the clinical outcome of recurrent breast cancer. OncoTargets Ther. 2017;10:4273–4281. doi: 10.2147/OTT.S139986.
    1. Lin M., Liang S.-Z., Shi J., Niu L.-Z., Chen J.-B., Zhang M.-J., Xu K.-C. Circulating tumor cell as a biomarker for evaluating allogenic NK cell immunotherapy on stage IV non-small cell lung cancer. Immunol. Lett. 2017;191:10–15. doi: 10.1016/j.imlet.2017.09.004.
    1. Qin Z., Chen J., Zeng J., Niu L., Xie S., Wang X., Liang Y., Wu Z., Zhang M. Effect of NK cell immunotherapy on immune function in patients with hepatic carcinoma: A preliminary clinical study. Cancer Biol. Ther. 2017;18:323–330. doi: 10.1080/15384047.2017.1310346.
    1. Guo C., Manjili M.H., Subjeck J.R., Sarkar D., Fisher P.B., Wang X.Y. Therapeutic cancer vaccines: Past, present, and future. Adv. Cancer Res. 2013;119:421–475.
    1. Romero P., Banchereau J., Bhardwaj N., Cockett M., Disis M.L., Dranoff G., Gilboa E., Hammond S.A., Hershberg R., Korman A.J., et al. The Human Vaccines Project: A roadmap for cancer vaccine development. Sci. Transl. Med. 2016;8:334ps9. doi: 10.1126/scitranslmed.aaf0685.
    1. Stojadinovic A., Mittendorf E.A., Holmes J.P., Amin A., Hueman M.T., Ponniah S., Peoples G.E. Quantification and Phenotypic Characterization of Circulating Tumor Cells for Monitoring Response to a Preventive HER2/neu Vaccine-Based Immunotherapy for Breast Cancer: A Pilot Study. Ann. Surg. Oncol. 2007;14:3359–3368. doi: 10.1245/s10434-007-9538-x.
    1. Birzele F., Voss E., Nopora A., Honold K., Heil F., Lohmann S., Verheul H., Le Tourneau C., Delord J.P., van Herpen C., et al. CD44 Isoform Status Predicts Response to Treatment with Anti-CD44 Antibody in Cancer Patients. Clin. Cancer Res. 2015;21:2753–2762. doi: 10.1158/1078-0432.CCR-14-2141.
    1. Maisel D., Birzele F., Voss E., Nopora A., Bader S., Friess T., Goller B., Laifenfeld D., Weigand S., Runza V. Targeting Tumor Cells with Anti-CD44 Antibody Triggers Macrophage-Mediated Immune Modulatory Effects in a Cancer Xenograft Model. PLoS ONE. 2016;11:e0159716. doi: 10.1371/journal.pone.0159716.
    1. Grugan K.D., McCabe F.L., Kinder M., Greenplate A.R., Harman B.C., Ekert J.E., van Rooijen N., Anderson G.M., Nemeth J.A., Strohl W.R., et al. Tumor-Associated Macrophages Promote Invasion while Retaining Fc-Dependent Anti-Tumor Function. J. Immunol. 2012;189:5457–5466. doi: 10.4049/jimmunol.1201889.
    1. Chan K.S., Espinosa I., Chao M., Wong D., Ailles L., Diehn M., Gill H., Presti J., Chang H.Y., van de Rijn M., et al. Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc. Natl. Acad. Sci. USA. 2009;106:14016–14021. doi: 10.1073/pnas.0906549106.
    1. Braun S., Hepp F., Kentenich C.R., Janni W., Pantel K., Riethmuller G., Willgeroth F., Sommer H.L. Monoclonal antibody therapy with edrecolomab in breast cancer patients: Monitoring of elimination of disseminated cytokeratin-positive tumor cells in bone marrow. Clin. Cancer Res. 1999;5:3999–4004.
    1. Schwartzberg L.S. Clinical experience with edrecolomab: A monoclonal antibody therapy for colorectal carcinoma. Crit. Rev. Oncol. Hematol. 2001;40:17–24. doi: 10.1016/S1040-8428(01)00131-7.
    1. Richter C.E., Cocco E., Bellone S., Silasi D.-A., Rüttinger D., Azodi M., Schwartz P.E., Rutherford T.J., Pecorelli S., Santin A.D. High-grade, chemotherapy-resistant ovarian carcinomas overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody. Am. J. Obstetr. Gynecol. 2010;203:582-e1. doi: 10.1016/j.ajog.2010.07.041.
    1. Seimetz D., Lindhofer H., Bokemeyer C. Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM×anti-CD3) as a targeted cancer immunotherapy. Cancer Treat. Rev. 2010;36:458–467. doi: 10.1016/j.ctrv.2010.03.001.
    1. Zaloudik J., Li W., Jacob L., Kieny M.P., Somasundaram R., Acres B., Song H., Zhang T., Li J., Herlyn D. Inhibition of tumor growth by recombinant vaccinia virus expressing GA733/CO17-1A/EpCAM/KSA/KS1-4 antigen in mice. Cancer Gene Ther. 2002;9:382–389. doi: 10.1038/sj.cgt.7700452.
    1. Chaudry M.A., Sales K., Ruf P., Lindhofer H., Winslet M.C. EpCAM an immunotherapeutic target for gastrointestinal malignancy: Current experience and future challenges. Br. J. Cancer. 2007;96:1013–1019. doi: 10.1038/sj.bjc.6603505.
    1. Mitchell M.J., Wayne E., Rana K., Schaffer C.B., King M.R. TRAIL-coated leukocytes that kill cancer cells in the circulation. Proc. Natl. Acad. Sci. USA. 2014;111:930–935. doi: 10.1073/pnas.1316312111.
    1. Mosolits S., Markovic K., Frodin J.E., Virving L., Magnusson C.G., Steinitz M., Fagerberg J., Mellstedt H. Vaccination with Ep-CAM protein or anti-idiotypic antibody induces Th1-biased response against MHC class I- and II-restricted Ep-CAM epitopes in colorectal carcinoma patients. Clin. Cancer Res. 2004;10:5391–5402. doi: 10.1158/1078-0432.CCR-04-0425.
    1. Choi Y.J., Park S.J., Park Y.S., Park H.S., Yang K.M., Heo K. EpCAM peptide-primed dendritic cell vaccination confers significant anti-tumor immunity in hepatocellular carcinoma cells. PLoS ONE. 2018;13:e0190638. doi: 10.1371/journal.pone.0190638.
    1. Hamilton D.H., David J.M., Dominguez C., Palena C. Development of Cancer Vaccines Targeting Brachyury, a Transcription Factor Associated with Tumor Epithelial-Mesenchymal Transition. Cells Tissues Organs. 2017;203:128–138. doi: 10.1159/000446495.
    1. Hackl H., Charoentong P., Finotello F., Trajanoski Z. Computational genomics tools for dissecting tumour-immune cell interactions. Nat. Rev. Genet. 2016;17:441–458. doi: 10.1038/nrg.2016.67.
    1. Ting D.T., Wittner B.S., Ligorio M., Vincent Jordan N., Shah A.M., Miyamoto D.T., Aceto N., Bersani F., Brannigan B.W., Xega K., et al. Single-cell RNA sequencing identifies extracellular matrix gene expression by pancreatic circulating tumor cells. Cell Rep. 2014;8:1905–1918. doi: 10.1016/j.celrep.2014.08.029.
    1. Miyamoto D.T., Zheng Y., Wittner B.S., Lee R.J., Zhu H., Broderick K.T., Desai R., Fox D.B., Brannigan B.W., Trautwein J., et al. RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance. Science. 2015;349:1351–1356. doi: 10.1126/science.aab0917.
    1. Andree K.C., Mentink A., Zeune L.L., Terstappen L., Stoecklein N.H., Neves R.P., Driemel C., Lampignano R., Yang L., Neubauer H., et al. Towards a real liquid biopsy in metastatic breast and prostate cancer: Diagnostic LeukApheresis increases CTC yields in a European prospective multi-center study (CTCTrap) Int. J. Cancer. 2018 doi: 10.1002/ijc.31752.
    1. Tagawa S.T., Scherr D., Batra J., Jhanwar Y., Robinson B., Nanus D., Beltran H., Molina A., Christos P., Bander N. Anti-prostate-specific membrane antigen (PSMA) monoclonal antibody (mAb) J591 immunotherapy for prostate cancer. Ann. Oncol. 2016;27:772TiP. doi: 10.1093/annonc/mdw372.55.
    1. Heery C.R., Palena C., McMahon S., Donahue R.N., Lepone L.M., Grenga I., Dirmeier U., Cordes L., Marte J., Dahut W., et al. Phase I Study of a Poxviral TRICOM-Based Vaccine Directed Against the Transcription Factor Brachyury. Clin. Cancer Res. 2017;23:6833–6845. doi: 10.1158/1078-0432.CCR-17-1087.
    1. Heery C.R., Donahue R., Lepone L., Grenga I., Richards J., Metenou S., Fernando R.I., Dirmeier U., Singh H., Madan R., et al. Phase I, dose-escalation, clinical trial of MVA-Brachyury-TRICOM vaccine demonstrating safety and brachyury-specific T cell responses. J. ImmunoTher. Cancer. 2015;3:P132. doi: 10.1186/2051-1426-3-S2-P132.
    1. Bidard F., cottu P., Dubot C., Venat-Bouvet L., Lortholary A., Bourgeois H., Bollet M., Hanon V.S., Luporsi-Gely E., Espie M., et al. 117P—Anti-HER2 therapy efficacy in HER2-negative metastatic breast cancer with HER2-amplified circulating tumor cells: Results of the CirCe T-DM1 trial. Ann. Oncol. 2017;28(Suppl. 5):v22–v42. doi: 10.1093/annonc/mdx363.033.
    1. Ignatiadis M., Rack B., Rothe F., Riethdorf S., Decraene C., Bonnefoi H., Dittrich C., Messina C., Beauvois M., Trapp E., et al. Liquid biopsy-based clinical research in early breast cancer: The EORTC 90091-10093 Treat CTC trial. Eur. J. Cancer. 2016;63:97–104. doi: 10.1016/j.ejca.2016.04.024.
    1. Imhof M., Lipovac M., Angleitner-Boubenizek L., Barta J., Gomez I., Hrdina A., Krupa E., Lafleur J., Lang I., Pieta K., et al. Double-loaded mature dendritic cell (DC) therapy for non-HLA-restricted patients with advanced ovarian cancer: Final results of a clinical phase I study. J. Clin. Oncol. 2013;31:3052.
    1. Van den Heuvel M.M., Verheij M., Boshuizen R., Belderbos J., Dingemans A.M., De Ruysscher D., Laurent J., Tighe R., Haanen J., Quaratino S. NHS-IL2 combined with radiotherapy: Preclinical rationale and phase Ib trial results in metastatic non-small cell lung cancer following first-line chemotherapy. J. Transl. Med. 2015;13:32. doi: 10.1186/s12967-015-0397-0.
    1. Madan R.A., Bilusic M., Hodge J.W., Tsang K.Y., Arlen P.M., Heery C.R., Rauckhorst M., McMahon S., Intrivici C., Ferrara T.A., et al. A phase I trial of a yeast-based therapeutic cancer vaccine targeting CEA. J Clin. Oncol. 2011;29:2604. doi: 10.1200/jco.2011.29.15_suppl.2604.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit